期刊
EBIOMEDICINE
卷 77, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2022.103941
关键词
Chimeric antigen receptor; CAR T; T cell exhaustion; Cancer; Immunotherapy
资金
- National Cancer Institute [K08CA201591]
- California Institute for Regenerative Medicine [CIRM CLIN2-12153]
- Pediatric Cancer Research Foundation
Chimeric antigen receptor (CAR) T cell therapy has shown impressive antitumor activity in the treatment of hematological malignancies, but CAR T cell exhaustion remains a major limitation. This review discusses the underlying mechanisms of exhaustion and emerging strategies to prevent or reverse exhaustion through modifications of the CAR receptor or CAR independent pathways. These strategies hold potential for improving the clinical outcomes of CAR T cell therapy.
Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with enormous potential, demonstrating impressive antitumor activity in the treatment of hematological malignancies. However, CART cell exhaustion is a major limitation to their efficacy, particularly in the application of CAR T cells to solid tumors. CAR T cell exhaustion is thought to be due to persistent antigen stimulation, as well as an immunosuppressive tumor microenvironment, and mitigating exhaustion to maintain CAR T cell effector function and persistence and achieve clinical potency remains a central challenge. Here, we review the underlying mechanisms of exhaustion and discuss emerging strategies to prevent or reverse exhaustion through modifications of the CAR receptor or CAR independent pathways. Additionally, we discuss the potential of these strategies for improving clinical outcomes of CART cell therapy. Copyright (c) 2022 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据